Leerink Partners Downgrades Mirati Therapeutics to Market Perform, Lowers Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Andrew Berens has downgraded Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Market Perform and lowered the price target from $78 to $58.
November 07, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirati Therapeutics has been downgraded by Leerink Partners from Outperform to Market Perform, with a reduced price target of $58.
The downgrade from Outperform to Market Perform by Leerink Partners, along with a reduced price target, indicates a less optimistic outlook for Mirati Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100